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Abstract: The outbreak of pneumonia originating in Wuhan, China, has generated 24,500 confirmed
cases, including 492 deaths, as of 5 February 2020. The virus (2019-nCoV) has spread elsewhere
in China and to 24 countries, including South Korea, Thailand, Japan and USA. Fortunately, there
has only been limited human-to-human transmission outside of China. Here, we assess the risk of
sustained transmission whenever the coronavirus arrives in other countries. Data describing the
times from symptom onset to hospitalisation for 47 patients infected early in the current outbreak
are used to generate an estimate for the probability that an imported case is followed by sustained
human-to-human transmission. Under the assumptions that the imported case is representative of
the patients in China, and that the 2019-nCoV is similarly transmissible to the SARS coronavirus,
the probability that an imported case is followed by sustained human-to-human transmission is 0.41
(credible interval [0.27, 0.55]). However, if the mean time from symptom onset to hospitalisation
can be halved by intense surveillance, then the probability that an imported case leads to sustained
transmission is only 0.012 (credible interval [0, 0.099]). This emphasises the importance of current
surveillance efforts in countries around the world, to ensure that the ongoing outbreak will not
become a global pandemic.
Keywords: 2019-nCoV; mathematical modelling; infectious disease epidemiology; major outbreak;
forecasting; coronavirus; Wuhan; SARS
1. Introduction
The infectious agent driving the ongoing pneumonia outbreak (the 2019-nCoV) appears to have
transitioned from animals into humans, with the Huanan seafood wholesale market in Wuhan, China,
representing the most likely source [1–5]. Since then, cases have been recorded in other countries,
and initial estimates suggest a hospital fatality risk of around 14% [6], although estimates of disease
severity early in an outbreak are often imprecise [7–9]. Even countries without confirmed cases have
been on high alert. For example, even prior to the two cases in the United Kingdom on 31 January
2020, officials were reported to be attempting to trace as many as 2000 visitors that had travelled to
that country from Wuhan [10].
The most devastating infectious disease outbreaks are those that have a wide geographical range,
as opposed to being confined to a small region [11,12]. The previously known virus that is most
similar to the 2019-nCoV is the SARS coronavirus [13], which generated cases in 37 countries in
2002–2003 [13,14]. Since the 2019-nCoV is clearly capable of being transmitted by infected hosts to
countries around the world, an important question for policy makers is whether or not these imported
cases have the potential to generate sustained human-to-human transmission in new locations.
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Here, we present data describing the times from symptom onset to hospitalisation for 47 patients
from the current outbreak, obtained from publicly available line lists [15]. We fit an exponential
distribution to these data, accounting for uncertainty due to the limited numbers of patients from
whom data were available. Assuming that this distribution characterises the time spent by infected
hosts generating new transmissions in the community, it is then possible to infer the probability that
a case arriving in a new location is followed by an outbreak driven by sustained human-to-human
transmission. We estimate this probability under the assumption that the transmissibility of the
2019-nCoV is similar to that of the SARS coronavirus, and then go on to consider the effect of shortening
the mean time from symptom onset to hospitalisation. This provides an estimate of the risk that
imported cases generate sustained outbreaks in new locations under different surveillance levels.
2. Methods
2.1. Time from Symptom Onset to Hospitalisation
The distribution of times from symptom onset to hospitalisation was estimated using patient data
from the ongoing outbreak [15] (data are shown in Figure 1A). Since the precise times of symptom onset
and hospitalisation on the dates concerned were unknown, we converted the times from symptom
onset to hospitalisation to intervals describing possible time periods (see the Supplementary Data). For
example, for a case showing symptoms on 9 January 2020, and then being hospitalised on 14 January
2020, the time between symptom onset and hospitalisation lies between four and six days (see e.g.,
Supplementary Material of [16] for a similar calculation). This is because the minimum possible period
involves symptom onset at the end of 9 January and hospitalisation at the start of 14 January, whereas
the maximum possible period involves symptom onset early on 9 January and hospitalisation late on
14 January.
We then fitted the rate parameter (γ) of an exponential distribution to these interval-censored
data using Markov chain Monte Carlo (MCMC). A chain of length 10,000,000 in addition to a burn-in
of 100,000 was used. The chain was then sampled with a thinning interval of 100 steps, giving rise n
= 100,000 equally possible distributions for the times from symptom onset to hospitalisation, each
characterised by a parameter estimate γi (i = 1, 2, . . . ,n). For further details of the MCMC algorithm
used, see the Supplementary Text.
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Figure 1. The probability of a self-sustaining outbreak driven by human-to-human transmission arising
following the importation of one infected individual. (A) Data describing the number of days between
symptom onset and hospitalisation for 47 patients in the ongoing outbreak [15]. (B) The estimated
distribution of times between symptom onset and hospitalisation, obtained by fitting to the data shown
in panel A. Blue lines show a range of equally possible distributions (see Methods; 50 distributions are
shown here, selected at random from the n = 100,000 distributions considered), and the red line shows
the average of the n = 100,000 distributions. (C) The probability of sustained transmission for each
possible distribution of times from symptom onset to hospitalisation (Equation (1); blue histogram)
and the probability of sustained transmission obtained by integrating over the possible distributions
(Equation (2); red line). (D) The probability that a single imported case leads to sustained transmission
in a new location, for different surveillance levels. The red line shows the mean estimates (obtained
using Equation (2) but extended to account for intensified surveillance), and the blue dotted lines show
the 5th and 95th percentile estimates (obtained when Equation (1) is applied, but extended to account
for intensified surveillance).
2.2. Estimating the Probability of Sustained Transmission
The distributions of times from symptom onset to hospitalisation were used to estimate the
probability that an imported case will lead to sustained transmission, by assuming that infections occur
according to a branching process (e.g., [17–19]). In this branching process, the effective reproduction
number (accounting for control interventions, other than intensified surveillance which we model
explicitly) of the 2019-nCoV when the virus arrives in a new location is denoted by R = β/γ, where
the parameter β represents pathogen transmissibility [20]. We assumed that the transmissibility of the
virus is similar to that of the SARS coronavirus, i.e., β = RSARSγSARS, where RSARS = 3 [21] and the
mean infection duration for SARS is 1/γSARS = 3.8 days [22]. However, we adjusted the infectious
period to account for the data describing the times between symptom onset and hospitalisation in
the current outbreak. In doing this, we assumed that the time between an individual first displaying
symptoms and being hospitalised was the period in which that individual was potentially transmitting
the virus in the community.
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The probability of a sustained transmission chain [19,20] starting from a single index case
can be estimated for each of the equally possible distributions for the time from symptom onset
to hospitalisation,
Prob(sustained transmission | γi) = 1− 1
(β/γi)
(1)
In this expression, it is assumed that β/γi > 1 (otherwise the probability of sustained transmission
takes the value zero). If required, this can then be combined into a single estimate for the probability
that an imported case leads to sustained transmission, p, given by
p =
1
n
n∑
i=1
Prob(sustained transmission | γi) (2)
To include intensified surveillance in these estimates, we simply replaced the mean time from
symptom onset to hospitalisation for each of the equally plausible distributions, 1/γi, by the modified
expression (1− ρ)/γi. In this approximation, the parameter ρ represents the proportional reduction in
the mean infectious period due to intensified surveillance.
2.3. Multiple Imported Cases
The risk of sustained transmission given multiple imported cases was calculated by considering
the possibility that none of those cases led to sustained transmission. Consequently,
Prob(sustained transmission | m imported cases, γi) = 1−
(
1
(β(1− ρ)/γi)
)m
(3)
In this expression, it is assumed that β(1− ρ)/γi > 1 (otherwise the probability of sustained
transmission takes the value zero). Again, if required, this can be combined into a single estimate for
the probability of sustained transmission starting from m imported cases, pm, given by
pm =
1
n
n∑
i=1
Prob(sustained transmission | m imported cases, γi) (4)
3. Results
As described in Methods, the distribution of times between symptom onset and hospitalisation
was estimated using Markov chain Monte Carlo (Figure 1B and Figure S1) from the patient data in
Figure 1A. This gave rise to a range of equally plausible distributions describing these time periods
(blue lines in Figure 1B). The average of these distributions is shown by the red line in Figure 1B,
however we used the full range of distributions in our calculations of the probability of sustained
transmission occurring from each imported case.
Each of the range of plausible distributions corresponded to an estimate for the probability
of a self-sustaining outbreak (Equation (1) and histogram in Figure 1C). A single estimate for the
probability of sustained transmission can be obtained by summing over the range of distributions
using Equation (2). The resulting probability of sustained transmission is 0.41 (red line in Figure 1C),
with credible interval (CrI) [0.27, 0.55], where the CrI reflects the 5th and 95th percentile estimates.
We then considered the reduction in the probability that an imported case leads to sustained
transmission if surveillance is more intense. Specifically, we assumed that intensified surveillance led
to a reduction in the mean period from symptom onset to hospitalisation, governed by the parameter ρ
(where ρ = 0 corresponds to no intensification of surveillance, and ρ = 1 corresponds to an implausible
scenario in which infectious cases are hospitalised immediately). We found that, if surveillance is
intensified so that the mean time from symptom onset to hospitalisation is halved, the probability that
each imported case leads to sustained transmission is reduced to only 0.012 (CrI [0, 0.099]; Figure 1D).
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Finally, we considered the combined effect if multiple cases arrive in a new location. In that
scenario, intense surveillance has the potential to reduce the risk of sustained transmission significantly
compared to weak surveillance. For ρ = 0.5, the probability that any of 10 imported cases generate a
substantial outbreak is only 0.12 (CrI [0, 0.65]; Figure 2C). This highlights the importance of rigorous
surveillance, particularly in locations where infected hosts are most likely to travel.
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Figure 2. The probability of a self-sustaining outbreak driven by human-to-human transmission arising
from multiple independent cases imported to a new location, under different surveillance levels. (A)
No intensification of surveillance (ρ = 0). (B) Medium level of surveilla ce int nsificatio (ρ = 0.25 ).
(C) High level of urveillance intens fication (ρ = 0.5 ). Th grey bars and red dots show he mean
estimates (obtained using Equation (4)), and the error bars indicate the 5th and 95th percentil estimates
obtained when Equation (3) is applied.
4. Discussion
There are concerns that the ongoing outbreak driven by the 2019-nCoV could spread
globally [3,5,23–25] with sustained transmission in countries around the world. Periods of high
travel rates, such as the recent Chinese New Year holiday, present a significant challenge since they
pose an elevated risk of importations of the virus to new locations [3,13]. In an effort to prevent a surge
in travel, the Chinese government extended the national New Year holiday in January 2020.
Here, we have estimated the potential for cases arriving in new locations to lead to sustained
transmission. According to the basic model that we have constructed, if surveillance levels are similar
to those in China at the beginning of the current outbreak, and if this virus is similarly transmissible
to the SARS coronavirus that spread globally in 2002–2003, then the probability that each imported
infected case generates an outbreak due to sustained transmission is approximately 0.41 (CrI [0.27, 0.55];
Figure 1C). However, under a higher level of surveillance, the risk of sustained outbreaks is substantially
lower (Figure 1D). This result is particularly striking when multiple independent cases travel to a new
location, either simultaneously or in sequence (Figure 2). In that scenario, intensified surveillance is
particularly important.
Our study involves the simplest possible model that permits the risk of sustained transmission
to be estimated from the very limited data that have been collected in this outbreak until now. As
additional information becomes available, it will be possible to estimate the risk of outbreaks in new
locations with more precision. We made the assumption that symptom appearance coincides with
the onset of infectiousness. One of the features of the SARS outbreak in 2002–2003 that allowed it
to eventually be brought under control was the low proportion of onward transmissions occurring
either prior to symptoms or from asymptomatic infectious hosts [26]. It might be hoped that infections
due to the 2019-nCoV share this characteristic. Some reports have suggested that this may not be the
case, although the extent of presymptomatic transmission is disputed [25,27]. We are working on an
updated version of our analyses that includes the possibility of transmission from presymptomatic or
mildly symptomatic hosts (based on the “SEAIR” compartmental model [19]).
Since our results were obtained using patient data from early in the ongoing outbreak, surveillance
systems may not have been fully established when these data were collected, and patients may not
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have been primed to respond quickly to early symptoms. Our results might therefore be viewed as an
upper bound on the risk posed by the 2019-nCoV. As the outbreak continues, it might be expected that
the time from symptom onset to hospitalisation or isolation will decrease, leading to lower risks of
sustained transmission, as has been observed for outbreaks of other diseases (e.g., the ongoing outbreak
of Ebola virus disease in the Democratic Republic of the Congo). Initial indications suggest that such
a decrease is occurring in China for this outbreak. In contrast, there may be some individuals that
developed symptoms, but had not yet reported their infection by the time our analysis was conducted.
“Right censoring” in this way favours lower reporting times, and so falsely reduces estimates of the
time between symptom onset and hospitalisation [16,28].
Going forwards, it will be possible to include additional realism in the model. One example
might be to consider spatial variation in host population densities and surveillance levels, leading to
spatially inhomogeneous outbreak risks. Another possibility might be to account more explicitly for
heterogeneities between different infectors, either by incorporating “superspreaders” [29] in the model
or by differentiating between individuals that report disease at different rates. Such heterogeneity
might be expected to reduce the risk of sustained transmission (for a preliminary analysis, in which
individuals can either be “fast reporters” or “slow reporters”, see the Supplementary Text). It would
also be possible to differentiate between mild and severe cases in the model. On the one hand, a mild
case might be more likely to go unnoticed than a severe case, potentially leading to a higher outbreak
risk. On the other hand, mild infections may generate fewer secondary cases than severe infections,
thereby decreasing the outbreak risk. Complex interactions may therefore affect the risk of sustained
transmission in an unpredictable fashion.
Despite the necessary simplifications made in this study, our analyses are sufficient to demonstrate
the key principle that rigorous surveillance is important to minimise the risk of the 2019-nCoV
generating large outbreaks in countries worldwide. We therefore support the ongoing work of
the World Health Organization and policy makers from around the world, who are working with
researchers and public health experts to manage this outbreak [2]. We also appreciate efforts to make
data publicly available [15]. Careful analysis of the outbreak, as well as minimisation of transmission
risk as much as possible, is of clear public health importance.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/2/498/s1.
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